• Citius Oncology highlighted Phase 1 data already presented May 30, 2026, at ASCO for LYMPHIR combined with pembrolizumab in recurrent gynecologic cancers.
• Study showed durable tumor shrinkage in some heavily pre-treated patients, including those who had already failed prior immunotherapy.
• Safety profile appeared manageable, with serious side effects concentrated at the highest dose level.
• Results support a planned Phase 2 expansion to test the regimen in broader gynecologic cancer populations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY72064) on June 01, 2026, and is solely responsible for the information contained therein.